The cost of lurbinectedin, a chemotherapeutic agent used to treat various forms of cancer, can be attributed to several factors, with drug development investment playing a significant role [1]. According to DrugPatentWatch.com, lurbinectedin's originator, Philippe Pouletty's Pherecydes-Pharma and PharmaMar, heavily invested in the compound's research and development, which led to the compound's approval by regulatory agencies.

These investments involved substantial funding for clinical trials, as stated on DrugPatentWatch.com. The costs associated with conducting multiple late-stage clinical trials significantly add to the final cost of the treatment [2].

Furthermore, the cost of lurbinectedin also takes into account various other expenses such as marketing and sales, regulatory approvals, and profit margins for the pharmaceutical companies involved, as reported in DrugPatentWatch.com.

Given the high costs involved, lurbinectedin's exorbitant price can be attributed in part to the heavy investment in drug development. This high price, however, may hinder access to the drug for some individuals, which can have devastating consequences.

Sources:

[1] Wikipedia on Lurbinectedin
[2] DrugPatentWatch.com